Healthcare Stock Gainers: Galena Biopharma Inc, Ariad Pharmaceuticals, Questcor Pharmaceuticals, Novogen Limited

Lakeway, TX -- (SBWIRE) -- 02/20/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Galena Biopharma Inc (NASDAQ:GALE) is higher 9.32% and ended at $2.00. Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.

How Should Investors Trade GALE After The Recent Movement? Find Out Here

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) added 5.10% and ended at $21.02. ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy.

Is ARIA Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) is higher 8.03% and ended at $30.95. Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company’s primary product is H.P. Acthar Gel (repository corticotropin injection) (Acthar), an injectable drug that is approved by the United States Food and Drug Administration, for the treatment of 19 indications.

Is QCOR a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Novogen Limited (ADR) (NASDAQ:NVGN) is higher 209.57% and ended at $6.47. Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. The Company has three segments: Drug Development, Oncology Drug Program, Consumer Business and Wound Healing.

How Should Investors Trade NVGN After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.